You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Hi, while going through the benchmark, I've noticed that the Tyk2 receptor contains the same mutations as 4GIH. In my opinion, these mutations should be reverted to wild type before running the FE calculations. While most of them are just entropy reducing mutations that have been introduced for X-ray crystallography (and are not close to the ligand-binding pocket), the D1023N mutation actually renders the kinase inactive which would indicate this was not the protein form used to determine the Ki values. This aspartate is a part of the HRD motif which sits close to the ligands in the ATP-binding site.
The text was updated successfully, but these errors were encountered:
Hi, while going through the benchmark, I've noticed that the Tyk2 receptor contains the same mutations as 4GIH. In my opinion, these mutations should be reverted to wild type before running the FE calculations. While most of them are just entropy reducing mutations that have been introduced for X-ray crystallography (and are not close to the ligand-binding pocket), the D1023N mutation actually renders the kinase inactive which would indicate this was not the protein form used to determine the Ki values. This aspartate is a part of the HRD motif which sits close to the ligands in the ATP-binding site.
The text was updated successfully, but these errors were encountered: